Latest news & pressroom
In the CombiGenes pressroom you will find press releases, newsletters, and the latest reports. High resolution images as well as logos are available for use in articles and in newsstands.
Copyright applies to all footage.
With the recruitment of Pernilla Fagergren, CombiGene strengthens the company further for the clinical studies in the epilepsy project CG01
In 2021, CombiGene's epilepsy project CG01 will focus on the final preclinical studies. In parallel, the company will intensify preparations for studies in humans, known as clinical studies, which are scheduled to begin in 2022. CombiGene has now recruited Pernilla...read more
BioStock has spoken with the newly recruited CMC expert Martin Linhult who, with his long experience of bringing pharmaceuticals to the market, will primarily focus on the manufacturing process of CG01, which is developed for the treatment of drug resistantfocal...read more
With the recruitment of Martin Linhult, CombiGene is starting the process to strengthen the company in preparation for the clinical studies in the epilepsy project CG01
In 2021, CombiGene's epilepsy project CG01 will focus on the final preclinical studies, not least the important biodistribution and toxicology studies, with the aim of starting studies in humans, so-called clinical studies, in 2022. A central area for both the final...read more
CombiGene has recently raised more than SEK 25 million through two successful warrants, which were excercised at 98.4 percent. At the same time, CombiGene's two gene therapy projects continue to be developed according to plan and the company's studies within the...read more
Associate Professor David Woldbye, one of CombiGene’s scientific founders, presents in a new peer-reviewed article in Frontiers in Molecular Neuroscience the outcome of CombiGene’s preclinical pharmacokinetic study, the company’s preclinical learning and memory study...read more
Find it easy
"This is an English translation of the Swedish website; if there is any inconsistency or ambiguity between the English version and the Swedish version, the Swedish version shall prevail. For a complete list of regulatory-related press releases, please refer to the Swedish website"
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 email@example.com.